Call for Papers  

Article Details

Assimilating Epigenetics and Transcriptomics for the Identification of Prognostic Novel Biomarkers and Imminent Targets in Colorectal Carcinoma with Therapeutic Potential

[ Vol. 23 , Issue. 8 ]


Suman Kumar Ray and Sukhes Mukherjee*   Pages 784 - 798 ( 15 )


Colorectal carcinoma (CRC), the foremost basis of malignancy-related death worldwide, evolves due to the stepwise amassing of a succession of genetic and epigenetic modifications. Epigenetic indicators are significant molecular hallmarks of malignancy. They play a big role in disease pathogenesis and are involved in almost all important cancer-related pathways. They can also be used as clinically useful cancer biomarkers for diagnosis, prognosis, and predicting how well treatment will work. Similarly, as gene changes in the malignant growth genome, a subset of driver genes attempts to play a useful part in CRC. Advances in our understanding of abnormal methylation in CRC have led to the development of epigenetic changes as diagnostic and prognostic biomarkers, and role of non-coding RNAs as epigenetic controllers. Beforehand, mass transcriptomics analysis is used to group CRC based on its distinctive molecular and clinicopathological features for prediction and patient analysis. The development of single-cell transcriptomics flipped the script by making it possible to evaluate the expression levels of particular neoplastic cells within a single tumor. Cell motility, growth, development, proliferation, DNA replication, recombination, their relationships with transcriptomics, and the CRC transcriptome analysis, have shown improvements. Progress in the appraisal of epigenetic alterations in CRC and their clinical applications has indicated that these changes will be ordinarily utilized as molecular markers to coordinate the anticipation and treatment of CRC. Recent improvements in our understanding of CRC and progress in genomics have led to the discovery of a number of epigenetic changes that are strongly linked to both the start and spread of cancer.


Colorectal carcinoma, epigenetics, transcriptomics, non-coding RNAs, driver genes, cancer biomarkers.


Read Full-Text article